Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 144,200 shares, an increase of 94.6% from the December 31st total of 74,100 shares. Based on an average trading volume of 55,400 shares, the short-interest ratio is currently 2.6 days. Currently, 1.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Akari Therapeutics in a report on Wednesday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Performance

Akari Therapeutics stock opened at $1.35 on Friday. Akari Therapeutics has a twelve month low of $0.90 and a twelve month high of $4.40. The business has a fifty day moving average of $1.16 and a two-hundred day moving average of $2.43.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.